BSL.SI Raffles Medical (SES) S$1.02 pre-market 21 Feb 2026: earnings 23 Feb could move stock

Raffles Medical Group (BSL.SI stock) trades at S$1.02 pre-market on 21 Feb 2026, with investors eyeing earnings due 23 Feb 2026. The company shows EPS S$0.03 and a PE of 34.33, with volume at 1,412,700 shares. Ahead of results, market attention will focus on margin recovery, outpatient flows across Singapore and Greater China, and guidance that could change short-term valuation. We set a clear checklist for what to watch in the report and how it ties to price and analyst forecasts.

BSL.SI stock: Earnings preview and what matters on 23 Feb

Raffles Medical (BSL.SI stock) reports results on 23 Feb 2026. Key metrics to watch are revenue growth, operating margin, and EPS versus S$0.03 consensus. Management commentary on China and regional expansion will matter for 2026 guidance. One positive beat on margins could compress the PE from 34.33 toward sector peers.

BSL.SI stock: Financials, valuation and sector comparison

Raffles Medical shows a market cap of S$1,900,140,472.00 and book value per share S$0.56. Price to book sits near 1.88 and dividend yield is 2.43%. The healthcare group trades above the sector average PE of 22.72, implying a premium for stable cash flow. Low debt with debt to equity 0.08 supports balance sheet resilience.

BSL.SI stock: Meyka AI grade and model forecast

Meyka AI rates BSL.SI with a score out of 100: 69.45 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly S$1.22, quarterly S$1.18, and yearly S$1.0964. Versus the current S$1.02, that implies short-term upside of 19.61% (monthly) and 7.49% (yearly). Forecasts are model-based projections and not guarantees.

BSL.SI stock: Technical snapshot and trading context pre-market

Technical indicators show a neutral-to-firm setup for BSL.SI stock. RSI is 58.67, ADX 36.84 signals a strong trend, and Bollinger bands sit at 1.02/1.00/0.98. Recent 50-day and 200-day averages are S$1.01 and S$1.00 respectively. Momentum and volume suggest buyers are present, but overbought CCI at 114.48 warns of a short-term pullback risk.

BSL.SI stock: Risks, catalysts and analyst angles

Earnings on 23 Feb are the immediate catalyst for BSL.SI stock. Risks include slower-than-expected patient volumes in Greater China, margin pressure from staffing costs, and weaker fee growth. Upside catalysts are margin improvement, clearer guidance on regional rollouts, and stronger diagnostics revenue. Absent a clear beat, the stock may revert toward its price-to-book fair value.

BSL.SI stock: Price targets, scenarios and portfolio fit

We set scenario-based targets for BSL.SI stock. Base-case near-term target is S$1.18 (quarterly forecast). Optimistic target is S$1.22 (monthly model), while a conservative 12‑month target uses Meyka’s yearly S$1.0964. For longer horizons, the model projects S$1.2691 in three years and S$1.44197 in five years. Use these as reference points, not guarantees.

Final Thoughts

Key takeaways for BSL.SI stock: the pre-market price of S$1.02 on 21 Feb 2026 already reflects steady cash flow and low leverage. Earnings on 23 Feb 2026 are the immediate trigger. Meyka AI’s forecast model projects S$1.0964 for the year, implying a 7.49% upside from today. Shorter-term model targets show larger moves, with the monthly projection at S$1.22 or 19.61% upside. Investors should weigh the elevated PE of 34.33 against a solid balance sheet and 2.43% dividend yield. Our Meyka AI grade is B (69.45, HOLD), reflecting mixed growth and valuation signals. Forecasts are model-based projections and not guarantees. For active traders, monitor the earnings beat or miss, conference-call guidance, and any region-specific updates that could swing sentiment.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.